Budd-Chiari syndrome

Summary

Budd-Chiari syndrome (MONDO:0010947) is a disease with 3 cohort genes and 6 clinical trials.

At a glance

• Prevalence: 1-9 / 100 000 (Worldwide) [Orphanet-validated]
• Cohort genes: 3
• ClinVar variants: 227
• Phenotypes (HPO): 23
• Clinical trials: 6

Clinical features

Epidemiology

Prevalence records

12 prevalence record(s), Orphanet:

Type	Class	Value	Geography	Validation
Annual incidence	1-9 / 1 000 000	0.1	Worldwide	Validated
Point prevalence	1-9 / 100 000	1.1	Worldwide	Validated
Point prevalence	1-9 / 100 000	1.5	Europe	Validated
Annual incidence	<1 / 1 000 000	0.08	Sweden	Validated
Annual incidence	<1 / 1 000 000	0.05	Denmark	Validated
Annual incidence	<1 / 1 000 000	0.02	Japan	Validated
Annual incidence	<1 / 1 000 000	0.04	France	Validated
Annual incidence	1-9 / 1 000 000	0.21	Italy	Validated
Annual incidence	<1 / 1 000 000	0.087	Korea, Republic of	Validated
Point prevalence	1-9 / 1 000 000	0.14	Sweden	Validated
Point prevalence	1-9 / 1 000 000	0.24	Japan	Validated
Point prevalence	1-9 / 1 000 000	0.529	Korea, Republic of	Validated

Signs & symptoms

Clinical features (HPO)

23 HPO clinical features (Orphanet curated; top 23 by frequency):

HPO ID	Term	Frequency
HP:0001409	Portal hypertension	Very frequent (80-99%)
HP:0001541	Ascites	Very frequent (80-99%)
HP:0001744	Splenomegaly	Very frequent (80-99%)
HP:0001394	Cirrhosis	Frequent (30-79%)
HP:0001945	Fever	Frequent (30-79%)
HP:0002027	Abdominal pain	Frequent (30-79%)
HP:0002040	Esophageal varix	Frequent (30-79%)
HP:0002240	Hepatomegaly	Frequent (30-79%)
HP:0002910	Elevated circulating hepatic transaminase concentration	Frequent (30-79%)
HP:0003155	Elevated circulating alkaline phosphatase concentration	Frequent (30-79%)
HP:0030243	Hepatic vein thrombosis	Frequent (30-79%)
HP:0033045	Bipedal edema	Frequent (30-79%)
HP:0000083	Renal insufficiency	Occasional (5-29%)
HP:0000952	Jaundice	Occasional (5-29%)
HP:0001082	Cholecystitis	Occasional (5-29%)
HP:0001824	Weight loss	Occasional (5-29%)
HP:0002024	Malabsorption	Occasional (5-29%)
HP:0002239	Gastrointestinal hemorrhage	Occasional (5-29%)
HP:0002480	Hepatic encephalopathy	Occasional (5-29%)
HP:0002586	Peritonitis	Occasional (5-29%)
HP:0005214	Intestinal obstruction	Occasional (5-29%)
HP:0005244	Gastrointestinal infarctions	Occasional (5-29%)
HP:0006554	Acute hepatic failure	Occasional (5-29%)

Identifiers

Disease identifiers

Field	Value
Canonical name	Budd-Chiari syndrome
Mondo ID	MONDO:0010947
MeSH	D006502
OMIM	600880
Orphanet	131
ICD-10-CM	I82.0
ICD-11	1300118676
SNOMED CT	82385007
UMLS	C0856761
MedGen	163632
GARD	0005968
MedDRA	10006537
Is cancer (heuristic)	no

Also known as: BDCHS · Budd-Chiari syndrome · Budd-Chiari syndrome, somatic · membranous obstruction of the inferior vena cava

Data availability: 227 ClinVar variants.

Disease family

Classification path: disease › human disease › disease by body system or component › digestive system disorder › hepatobiliary disorder › liver disorder › hepatic vascular disorder › Budd-Chiari syndrome

Related subtypes (10): portal vein thrombosis, hepatic infarction, nutmeg liver, liver angiosarcoma, peliosis hepatis, portal hypertension, hepatic vein thrombosis, hepatic veno-occlusive disease, portosinusoidal vascular disease, Fontan-associated liver disease

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

ClinVar germline variants

227 retrieved; paginated sample, class counts are floors:

87 uncertain significance, 71 conflicting classifications of pathogenicity, 45 benign/likely benign, 8 benign, 6 likely pathogenic, 4 pathogenic/likely pathogenic, 3 likely benign, 2 pathogenic, 1 drug response

ClinVar	Variant (HGVS)	Gene	Classification	Review
2734021	NM_000130.5(F5):c.3088C>T (p.Arg1030Ter)	F5	Pathogenic	criteria provided, multiple submitters, no conflicts
2866617	NM_000130.5(F5):c.5453del (p.Leu1818fs)	F5	Pathogenic/Likely pathogenic	criteria provided, multiple submitters, no conflicts
2895285	NM_000130.5(F5):c.2021del (p.Lys674fs)	F5	Pathogenic/Likely pathogenic	criteria provided, multiple submitters, no conflicts
430053	NM_000130.5(F5):c.5037dup (p.Ser1680fs)	F5	Pathogenic	criteria provided, multiple submitters, no conflicts
627264	NM_000130.5(F5):c.1830_1831dup (p.His611fs)	F5	Pathogenic/Likely pathogenic	criteria provided, multiple submitters, no conflicts
14662	NM_004972.4(JAK2):c.1849G>T (p.Val617Phe)	INSL6	Pathogenic/Likely pathogenic	criteria provided, multiple submitters, no conflicts
2887062	NM_000130.5(F5):c.4962_4971+3del	F5	Likely pathogenic	criteria provided, multiple submitters, no conflicts
3600169	NM_000130.5(F5):c.5816T>G (p.Leu1939Ter)	F5	Likely pathogenic	criteria provided, single submitter
3600193	NM_000130.5(F5):c.2846del (p.Leu949fs)	F5	Likely pathogenic	criteria provided, single submitter
3600196	NM_000130.5(F5):c.2079T>G (p.Tyr693Ter)	F5	Likely pathogenic	criteria provided, single submitter
3600213	NM_000130.5(F5):c.1297-1G>C	F5	Likely pathogenic	criteria provided, single submitter
3600215	NM_000130.5(F5):c.1059del (p.Phe353fs)	F5	Likely pathogenic	criteria provided, single submitter
642	NM_000130.4(F5):c.1601G>A (p.Arg534Gln)	F5	drug response	reviewed by expert panel
1771009	NM_000130.5(F5):c.136C>G (p.Arg46Gly)	F5	Conflicting classifications of pathogenicity	criteria provided, conflicting classifications
255209	NM_000130.5(F5):c.5177G>A (p.Arg1726Gln)	F5	Conflicting classifications of pathogenicity	criteria provided, conflicting classifications
293550	NM_000130.5(F5):c.*1290G>A	F5	Conflicting classifications of pathogenicity	criteria provided, conflicting classifications
293557	NM_000130.5(F5):c.*838T>C	F5	Conflicting classifications of pathogenicity	criteria provided, conflicting classifications
293560	NM_000130.5(F5):c.*581C>A	F5	Conflicting classifications of pathogenicity	criteria provided, conflicting classifications
293574	NM_000130.5(F5):c.6360G>A (p.Lys2120=)	F5	Conflicting classifications of pathogenicity	criteria provided, conflicting classifications
293575	NM_000130.5(F5):c.6309G>A (p.Leu2103=)	F5	Conflicting classifications of pathogenicity	criteria provided, conflicting classifications
293577	NM_000130.5(F5):c.5788+4A>T	F5	Conflicting classifications of pathogenicity	criteria provided, conflicting classifications
293578	NM_000130.5(F5):c.5721T>C (p.Cys1907=)	F5	Conflicting classifications of pathogenicity	criteria provided, conflicting classifications
293579	NM_000130.5(F5):c.5589C>A (p.Pro1863=)	F5	Conflicting classifications of pathogenicity	criteria provided, conflicting classifications
293582	NM_000130.5(F5):c.5490G>A (p.Leu1830=)	F5	Conflicting classifications of pathogenicity	criteria provided, conflicting classifications
293585	NM_000130.5(F5):c.5419+11C>G	F5	Conflicting classifications of pathogenicity	criteria provided, conflicting classifications
293589	NM_000130.5(F5):c.5124C>T (p.Tyr1708=)	F5	Conflicting classifications of pathogenicity	criteria provided, conflicting classifications
293590	NM_000130.5(F5):c.5054C>G (p.Thr1685Ser)	F5	Conflicting classifications of pathogenicity	criteria provided, conflicting classifications
293592	NM_000130.5(F5):c.4972-14A>C	F5	Conflicting classifications of pathogenicity	criteria provided, conflicting classifications
293594	NM_000130.5(F5):c.4835A>T (p.Asp1612Val)	F5	Conflicting classifications of pathogenicity	criteria provided, conflicting classifications
293595	NM_000130.5(F5):c.4405T>C (p.Ser1469Pro)	F5	Conflicting classifications of pathogenicity	criteria provided, conflicting classifications

Genes & proteins

Mendelian disease overlap and somatic drivers

GenCC: 0 · Orphanet: 12 · OMIM-shared: 0 · Dual-evidence (GWAS+Mendelian): 0

Orphanet rare-disease linkage (cohort genes)

Gene	Orphanet ID	Rare disease
F5	Orphanet:131	Budd-Chiari syndrome
F5	Orphanet:326	Congenital factor V deficiency
F5	Orphanet:329217	Cerebral sinovenous thrombosis
F5	Orphanet:391320	East Texas bleeding disorder
F5	Orphanet:599579	Factor V Amsterdam bleeding disorder
F5	Orphanet:600194	Factor V Atlanta bleeding disorder
JAK2	Orphanet:131	Budd-Chiari syndrome
JAK2	Orphanet:3318	Essential thrombocythemia
JAK2	Orphanet:667662	Breast implant-associated anaplastic large cell lymphoma
JAK2	Orphanet:71493	Familial thrombocytosis
JAK2	Orphanet:729	Polycythemia vera
JAK2	Orphanet:824	Primary myelofibrosis

Cohort genes → proteins

3 cohort genes, 3 distinct canonical proteins.

Evidence partition

Subset	Genes
multi_evidence	3

Cohort genes (full)

Symbol	HGNC	Ensembl	UniProt	Name	Evidence
F5	HGNC:3542	ENSG00000198734	P12259	Coagulation factor V	clinvar
INSL6	HGNC:6089	ENSG00000120210	Q9Y581	Insulin-like peptide INSL6	clinvar
JAK2	HGNC:6192	ENSG00000096968	O60674	Tyrosine-protein kinase JAK2	clinvar

Cohort function summary

Lead sentence per gene, UniProt-curated.

Symbol	Protein name	Function (lead sentence)
F5	Coagulation factor V	Central regulator of hemostasis.
INSL6	Insulin-like peptide INSL6	May have a role in sperm development and fertilization.
JAK2	Tyrosine-protein kinase JAK2	Non-receptor tyrosine kinase involved in various processes such as cell growth, development, differentiation or histone modifications.

Protein-family classification

Druggable: 1 · Difficult: 0 · Unknown: 2 · Druggable fraction: 0.33

Family distribution

Cohort families vs a genome-wide background (hypergeometric, BH-FDR; fold = observed/expected). Counts kept; sorted by enrichment, so the catch-all Other/Unknown bucket no longer leads.

Family	Genes	Fold	FDR
Kinase	1	9.2×	0.209
Other/Unknown	2	1.2×	0.587

Per-gene assignment

Symbol	Family	Druggable?	EC	InterPro (top 3)
F5	Other/Unknown	no		FA58C, Cupredoxin, Galactose-bd-like_sf
INSL6	Other/Unknown	no		Insulin-like, Insulin-like_pep_6, Insulin_CS
JAK2	Kinase	yes	2.7.10.2	FERM_domain, Prot_kinase_dom, SH2

Expression context

Cohort genes with no expression data: 0.

3 cohort genes are a single-cell marker in ≥1 SCXA experiment.

Breadth distribution (Bgee present_calls)

Bucket	Genes
narrow (1-5 tissues)	0
moderate (6-20)	0
broad (>20)	3
unknown	0

Top tissues across cohort

Tissue	Cohort genes
choroid plexus epithelium	1
liver	1
right lobe of liver	1
left testis	1
male germ line stem cell (sensu Vertebrata) in testis	1
right testis	1
blood vessel layer	1
calcaneal tendon	1
monocyte	1

Per-gene tissue summary (top 30)

Symbol	Bgee breadth	FANTOM5 breadth	SCXA	Top tissues
F5	206	broad	marker	right lobe of liver, liver, choroid plexus epithelium
INSL6	152	tissue_specific	marker	male germ line stem cell (sensu Vertebrata) in testis, left testis, right testis
JAK2	272	ubiquitous	marker	calcaneal tendon, monocyte, blood vessel layer

Protein interactions among cohort

Intra-cohort edges: 0.

Hub genes (top 10 by interactor count)

Symbol	Interactor count
JAK2	6,197
F5	1,754
INSL6	509

Structural data

PDB: 2 · AlphaFold-only: 1 · No structure: 0

Cohort genes with PDB structures (top 30)

Symbol	UniProt	PDB entries
JAK2	O60674	164
F5	P12259	18

AlphaFold-only cohort genes (top 30 by pLDDT)

Symbol	UniProt	pLDDT
INSL6	Q9Y581	54.46

Function

Pathway analysis

Distinct Reactome pathways touched by cohort: 76. Enrichment computed across 3 evidence-associated genes (2 with Reactome annotation).

Pathways by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 2 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

Pathway	Cohort genes	Fold	FDR	Sample cohort genes
Defective cleavage of FV variant at a.a.534	1	1903.3×	0.010	F5
Defective cleavage of FV variant at R334	1	1903.3×	0.010	F5
Erythropoietin activates Phospholipase C gamma (PLCG)	1	815.7×	0.010	JAK2
Erythropoietin activates STAT5	1	815.7×	0.010	JAK2
Interleukin-6 family signaling	1	713.8×	0.010	JAK2
IFNG signaling activates MAPKs	1	713.8×	0.010	JAK2
Interleukin-23 signaling	1	634.4×	0.010	JAK2
MAPK1 (ERK2) activation	1	571.0×	0.010	JAK2
Signaling by KIT in disease	1	571.0×	0.010	JAK2
MAPK3 (ERK1) activation	1	519.1×	0.010	JAK2
Signaling by Leptin	1	519.1×	0.010	JAK2
Signaling by Erythropoietin	1	519.1×	0.010	JAK2
Interleukin-27 signaling	1	519.1×	0.010	JAK2
Interleukin-6 signaling	1	475.8×	0.010	JAK2
Interleukin-35 Signalling	1	475.8×	0.010	JAK2
Erythropoietin activates Phosphoinositide-3-kinase (PI3K)	1	475.8×	0.010	JAK2
Regulation of IFNG signaling	1	407.9×	0.010	JAK2
Prolactin receptor signaling	1	380.7×	0.010	JAK2
Erythropoietin activates RAS	1	380.7×	0.010	JAK2
RAF-independent MAPK1/3 activation	1	317.2×	0.010	JAK2
Interleukin-2 family signaling	1	317.2×	0.010	JAK2
IL-6-type cytokine receptor ligand interactions	1	317.2×	0.010	JAK2
Amplification and propagation of coagulation cascade	1	317.2×	0.010	F5
Signaling by CSF3 (G-CSF)	1	285.5×	0.011	JAK2
Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants	1	259.6×	0.011	JAK2
Interleukin-12 family signaling	1	237.9×	0.011	JAK2
Initiation of coagulation cascade	1	237.9×	0.011	F5
Growth hormone receptor signaling	1	237.9×	0.011	JAK2
Inactivation of CSF3 (G-CSF) signaling	1	219.6×	0.011	JAK2
Signaling by RAS mutants	1	211.5×	0.011	JAK2

GO biological processes by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 2 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

GO term	Cohort genes	Fold	FDR	Sample cohort genes
nuclear receptor-mediated mineralocorticoid signaling pathway	1	8426.0×	0.004	JAK2
symbiont-induced defense-related programmed cell death	1	8426.0×	0.004	JAK2
interleukin-35-mediated signaling pathway	1	8426.0×	0.004	JAK2
response to interleukin-12	1	4213.0×	0.004	JAK2
positive regulation of growth factor dependent skeletal muscle satellite cell proliferation	1	4213.0×	0.004	JAK2
regulation of postsynapse to nucleus signaling pathway	1	4213.0×	0.004	JAK2
response to vitamin K	1	2808.7×	0.004	F5
positive regulation of growth hormone receptor signaling pathway	1	2808.7×	0.004	JAK2
collagen-activated signaling pathway	1	2106.5×	0.004	JAK2
granulocyte-macrophage colony-stimulating factor signaling pathway	1	2106.5×	0.004	JAK2
activation of Janus kinase activity	1	2106.5×	0.004	JAK2
post-embryonic hemopoiesis	1	1404.3×	0.004	JAK2
cellular response to interleukin-3	1	1404.3×	0.004	JAK2
interleukin-5-mediated signaling pathway	1	1404.3×	0.004	JAK2
interleukin-23-mediated signaling pathway	1	1404.3×	0.004	JAK2
erythropoietin-mediated signaling pathway	1	1404.3×	0.004	JAK2
positive regulation of NK T cell proliferation	1	1404.3×	0.004	JAK2
positive regulation of leukocyte proliferation	1	1404.3×	0.004	JAK2
interleukin-3-mediated signaling pathway	1	1203.7×	0.004	JAK2
thrombopoietin-mediated signaling pathway	1	1053.2×	0.004	JAK2
interleukin-12-mediated signaling pathway	1	936.2×	0.004	JAK2
mammary gland epithelium development	1	936.2×	0.004	JAK2
response to hydroperoxide	1	842.6×	0.004	JAK2
regulation of nitric oxide biosynthetic process	1	842.6×	0.004	JAK2
growth hormone receptor signaling pathway via JAK-STAT	1	766.0×	0.004	JAK2
negative regulation of protein localization to chromatin	1	766.0×	0.004	JAK2
positive regulation of natural killer cell proliferation	1	702.2×	0.004	JAK2
regulation of receptor signaling pathway via JAK-STAT	1	702.2×	0.004	JAK2
positive regulation of T-helper 17 type immune response	1	702.2×	0.004	JAK2
enzyme-linked receptor protein signaling pathway	1	648.1×	0.004	JAK2

Therapeutics

Drug target analysis

Approved (phase 4): 2 · Phase ≥3: 2 · Phased (≥1): 2 · Undrugged: 1

Druggability breadth: 2 of 3 evidence-associated genes (67%) have a ChEMBL target (buckets above are over the deeply-mined display cohort).

Genes with an approved drug

The molecule shown is one approved compound that hits the gene — not necessarily a drug of choice or one indicated for this disease.

Symbol	Example approved molecule
F5	EDOXABAN
JAK2	FEDRATINIB

Top cohort targets by molecule count

Symbol	Molecules	Max phase
JAK2	100	4
F5	2	4
INSL6	0	0

Drugs targeting cohort genes (top 30)

Molecule	Max phase	Targets in cohort
EDOXABAN	4	F5
FEDRATINIB	4	JAK2
RUXOLITINIB	4	JAK2
TOFACITINIB	4	JAK2
UPADACITINIB	4	JAK2
MOMELOTINIB	4	JAK2
PONATINIB	4	JAK2
AXITINIB	4	JAK2
NICLOSAMIDE	4	JAK2
RUXOLITINIB PHOSPHATE	4	JAK2
INFIGRATINIB PHOSPHATE	4	JAK2
INFIGRATINIB	4	JAK2
ENTRECTINIB	4	JAK2
DABRAFENIB	4	JAK2
PACRITINIB	4	JAK2
TOFACITINIB CITRATE	4	JAK2
BARICITINIB	4	JAK2
CERITINIB	4	JAK2
BOSUTINIB	4	JAK2
PEFICITINIB	4	JAK2
LORLATINIB	4	JAK2
FILGOTINIB	4	JAK2
BRIGATINIB	4	JAK2
ABROCITINIB	4	JAK2
REPOTRECTINIB	4	JAK2
DEUCRAVACITINIB	4	JAK2
PRALSETINIB	4	JAK2
CRAVACITINIB	4	JAK2
PAZOPANIB	4	JAK2
NINTEDANIB	4	JAK2

Bioactivity and enzyme data

Enzyme cohort genes (≥1 EC): 1.

Cohort genes with ChEMBL bioactivity (full, sorted by assay count)

Symbol	Assays	Type breakdown
JAK2	2,018	Binding:1911, Functional:51, ADMET:48, Unclassified:4, Toxicity:4
F5	10	Binding:10

Cohort enzymes (BRENDA EC)

Symbol	EC numbers	Names
JAK2	2.7.10.2	non-specific protein-tyrosine kinase

Cohort genes with high screening signal

≥100 ChEMBL assays — a studied-ness signal; see Therapeutics for approved-drug status.

Symbol	ChEMBL assays
JAK2	2,018

Pharmacogenomics

Cohort genes with a PharmGKB record: 3; with CPIC/DPWG dosing guidelines: 0.

No cohort gene has a CPIC/DPWG genotype-guided dosing guideline (PharmGKB).

Chemical tractability of cohort targets

30 approved/phased compounds have measured bioactivity against a cohort gene (and aren’t yet in disease-level trials). This is a research / tractability signal, NOT a therapeutic recommendation — a bioactivity row often reflects off-target or screening binding (e.g. promiscuous kinase inhibitors against a cohort kinase), implying no disease mechanism.

Compound	Max phase	Cohort target (bioactivity)
EDOXABAN	4	F5
FEDRATINIB	4	JAK2
RUXOLITINIB	4	JAK2
TOFACITINIB	4	JAK2
UPADACITINIB	4	JAK2
MOMELOTINIB	4	JAK2
PONATINIB	4	JAK2
AXITINIB	4	JAK2
NICLOSAMIDE	4	JAK2
RUXOLITINIB PHOSPHATE	4	JAK2
INFIGRATINIB PHOSPHATE	4	JAK2
INFIGRATINIB	4	JAK2
ENTRECTINIB	4	JAK2
DABRAFENIB	4	JAK2
PACRITINIB	4	JAK2
TOFACITINIB CITRATE	4	JAK2
BARICITINIB	4	JAK2
CERITINIB	4	JAK2
BOSUTINIB	4	JAK2
PEFICITINIB	4	JAK2
LORLATINIB	4	JAK2
FILGOTINIB	4	JAK2
BRIGATINIB	4	JAK2
ABROCITINIB	4	JAK2
REPOTRECTINIB	4	JAK2
DEUCRAVACITINIB	4	JAK2
PRALSETINIB	4	JAK2
CRAVACITINIB	4	JAK2
PAZOPANIB	4	JAK2
NINTEDANIB	4	JAK2

Druggability pyramid

Cohort genes binned by druggability tier (high → low):

Tier	Definition	Genes	Symbols
A	Approved (phase 4 drug)	2	F5, JAK2
B	Phased (≥1) drug, not yet approved	0
C	Druggable family + PDB, no drug	0
D	Druggable family + AlphaFold only, no drug	0
E	Difficult family or no structure, no drug	1	INSL6

Undrugged target profiles

1 cohort genes are undrugged. Ranked by ‘starting-point quality’ (assay depth + drugged-partner adjacency).

Symbol	ChEMBL assays	Drugged partners (top 3)
INSL6	0	—

Clinical trials & evidence

Clinical trials

Clinical trials: 6.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	6

Top trials by phase / activity

NCT	Phase	Status	Title
NCT05782556	Not specified	RECRUITING	Freiburg TIPS Registry
NCT06960473	Not specified	NOT_YET_RECRUITING	A Prospective Study on IVUS and DSA Guidance in the Treatment of Budd-Chiari Syndrome
NCT02201485	Not specified	COMPLETED	Budd-Chiari Syndrome in China: Balloon Angioplasty Alone or Combined With Stent Placement?
NCT03541057	Not specified	UNKNOWN	Vienna Vascular Liver Disease Study
NCT05117684	Not specified	COMPLETED	To Compare Balloon Occluded Thrombolysis With Conventional Catheter Directed Thrombolysis in Thrombotically Occluded DIPSS Stent in Patients of Budd- Chiari Syndrome.
NCT06054451	Not specified	UNKNOWN	Clinical Diagnosis and Pathological Spectrum of Porto-sinusoidal Vascular Disease in India